RO 7269162
Alternative Names: RO-7269162Latest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator Roche
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 10 Dec 2024 Hoffmann-La Roche plans phase I trial (In volunteers, In adults) (PO) in January 2025 (NCT06733298)
- 07 Jun 2024 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Netherlands (PO) (EudraCT2024-510732-52-00) (ISRCTN84512041)
- 23 May 2024 Hoffmann-La Roche plans a phase I trial for Alzheimer's disease (In Volunteers) in Netherlands (PO) in June 2024 (EudraCT2024-510732-52-00) (ISRCTN84512041)